Research programme: T cell therapeutics - Celgene/Juno Therapeutics
Alternative Names: Autoimmune disorder therapeutics - Celgene/Juno; Cancer therapeutics - Celgene/Juno; CAR T cell products - Celgene/Juno; Chimeric antigen receptor T lymphocytes - Celgene/Juno; TCR T cell products - Celgene/JunoLatest Information Update: 03 Dec 2019
At a glance
- Originator Celgene Corporation; Juno Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jul 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)